Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies

Expert Rev Anticancer Ther. 2016 Sep;16(9):897-8. doi: 10.1080/14737140.2016.1212664. Epub 2016 Jul 22.
No abstract available

Keywords: BTK inhibitor; NAD+ depletion; Novel therapies; lymphomas; tumor metabolism.

Publication types

  • Editorial

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Cytokines / antagonists & inhibitors
  • Drug Resistance, Neoplasm
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / pathology
  • Humans
  • NAD / metabolism*
  • Nicotinamide Phosphoribosyltransferase / antagonists & inhibitors

Substances

  • Cytokines
  • NAD
  • Nicotinamide Phosphoribosyltransferase
  • nicotinamide phosphoribosyltransferase, human